Real-world Cohort Study on the Effectiveness and Safety of Filgotinib Use in Ulcerative Colitis.

ABSTRACT:

Background

Filgotinib is a small molecule with preferential inhibition of Janus kinase type 1, approved for the treatment of ulcerative colitis in Scotland in May 2022. We present the first real-world experience on its use in clinical practice.

Methods

In this retrospective, observational, cohort study we assessed patients with active ulcerative colitis who received filgotinib in NHS Lothian, Scotland. Baseline demographic, phenotype, and follow-up data were collected via review of electronic medical records.

Results

We included 91 patients with median treatment duration of 39 weeks (interquartile range [IQR] 23-49). Among the cohort, 67% [61/91] were biologic- and small molecule-naïve, and 20.9% [19/91] had failed one and 12.1% [11/91]  two or more classes of advance

SUBMITTER: Gros B 

PROVIDER: S-EPMC11760993 | biostudies-literature | 2025 Jan

REPOSITORIES: biostudies-literature